Physician profile
John V Spence
NPI 1124034996
$569.23
in general payments reported to CMS, 2019-2025
10 companies · $72.10 in 2025
The $72.10 reported for 2025 was less than what a typical Undersea and Hyperbaric Medicine (Emergency Medicine) provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $69.37 · 2021: $78.59 · 2023: $14.90 · 2024: $138 · 2025: $72.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $155.43 | 2019-2025 | Apligraf, Puraply |
| Acera Surgical, INC. | $65.30 | 2021 | |
| Smith+Nephew, INC. | $61.20 | 2019-2020 | |
| Abiomed | $57.75 | 2020 | |
| Integra Lifesciences Corporation | $49.56 | 2024 | Tcc-Ez |
| Allergan, INC. | $47.69 | 2019 | |
| Kerecis Limited | $37.43 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Aroa Biosurgery Incorporated | $35.70 | 2019-2025 | |
| Abbvie INC. | $32.15 | 2021-2025 | |
| Tactile Systems Technology INC | $27.02 | 2024 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.